Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Cell Therapeutics, a biopharmaceutical company, has executed a definitive collaborative agreement with IDIS, a developer and implementer of named patient programs, to manage its investigational drug pixantrone on a named patient basis in Europe.
Subscribe to our email newsletter
Pixantrone will be supplied by IDIS to healthcare professionals for the treatment of individual patients with relapsing aggressive non-Hodgkin’s lymphoma. This program is expected to be initiated by the second quarter of 2009.
Craig Philips, President of Cell Therapeutics (CTI), said: “Under the named patient program, CTI will be able to provide pixantrone to European patients in need at the prescriber’s request while moving it through the approval process in the US.
“With the announcement of preliminary results showing significantly higher rate of complete remission and improvement in progression-free survival for patients receiving pixantrone compared to standard chemotherapeutic agents, we expect to receive a number of requests for pixantrone to treat specific patients.”